These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 29076032)

  • 41. Intracellular Tenofovir and Emtricitabine Anabolites in Genital, Rectal, and Blood Compartments from First Dose to Steady State.
    Seifert SM; Chen X; Meditz AL; Castillo-Mancilla JR; Gardner EM; Predhomme JA; Clayton C; Austin G; Palmer BE; Zheng JH; Klein B; Kerr BJ; Guida LA; Rower C; Rower JE; Kiser JJ; Bushman LR; MaWhinney S; Anderson PL
    AIDS Res Hum Retroviruses; 2016; 32(10-11):981-991. PubMed ID: 27526873
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Optimizing Pre-Exposure Antiretroviral Prophylaxis Adherence in Men Who Have Sex with Men: Results of a Pilot Randomized Controlled Trial of "Life-Steps for PrEP".
    Mayer KH; Safren SA; Elsesser SA; Psaros C; Tinsley JP; Marzinke M; Clarke W; Hendrix C; Wade Taylor S; Haberer J; Mimiaga MJ
    AIDS Behav; 2017 May; 21(5):1350-1360. PubMed ID: 27848089
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Medication Adherence in a Nationwide Cohort of Veterans Initiating Pre-exposure Prophylaxis (PrEP) to Prevent HIV Infection.
    van Epps P; Maier M; Lund B; Howren MB; Beck B; Beste L; Skolnik A; Vaughan-Sarrazin M; Ohl ME
    J Acquir Immune Defic Syndr; 2018 Mar; 77(3):272-278. PubMed ID: 29210835
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Stable Caloric Intake and Continued Virologic Suppression for HIV-Positive Antiretroviral Treatment-Experienced Women After Switching to a Single-Tablet Regimen of Emtricitabine, Rilpivirine, and Tenofovir Disoproxil Fumarate.
    Menezes P; Mollan K; Hoffman E; Xie Z; Wills J; Marcus C; Rublein J; Hudgens M; Eron JJ
    AIDS Res Hum Retroviruses; 2018 Jun; 34(6):481-485. PubMed ID: 29607652
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis.
    Glidden DV; Mulligan K; McMahan V; Anderson PL; Guanira J; Chariyalertsak S; Buchbinder SP; Bekker LG; Schechter M; Grinsztejn B; Grant RM
    J Acquir Immune Defic Syndr; 2017 Oct; 76(2):177-182. PubMed ID: 28639995
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A randomized clinical pharmacokinetic trial of Tenofovir in blood, plasma and urine in adults with perfect, moderate and low PrEP adherence: the TARGET study.
    Cressey TR; Siriprakaisil O; Klinbuayaem V; Quame-Amaglo J; Kubiak RW; Sukrakanchana PO; Than-In-At K; Baeten J; Sirirungsi W; Cressey R; Drain PK
    BMC Infect Dis; 2017 Jul; 17(1):496. PubMed ID: 28705153
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Changes in Kidney Function Associated With Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration Project.
    Tang EC; Vittinghoff E; Anderson PL; Cohen SE; Doblecki-Lewis S; Bacon O; Coleman ME; Buchbinder SP; Chege W; Kolber MA; Elion R; Shlipak M; Liu AY
    J Acquir Immune Defic Syndr; 2018 Feb; 77(2):193-198. PubMed ID: 28991887
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Decreased Absorption of Dolutegravir and Tenofovir Disoproxil Fumarate, But Not Emtricitabine, in an HIV-Infected Patient Following Oral and Jejunostomy-Tube Administration.
    Brooks KM; Garrett KL; Kuriakose SS; George JM; Balba G; Bailey B; Anderson M; Lane HC; Maldarelli F; Pau AK
    Pharmacotherapy; 2017 Aug; 37(8):e82-e89. PubMed ID: 28556353
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Factors associated with the uptake of and adherence to HIV pre-exposure prophylaxis in people who have injected drugs: an observational, open-label extension of the Bangkok Tenofovir Study.
    Martin M; Vanichseni S; Suntharasamai P; Sangkum U; Mock PA; Chaipung B; Worrajittanon D; Leethochawalit M; Chiamwongpaet S; Kittimunkong S; Gvetadze RJ; McNicholl JM; Paxton LA; Curlin ME; Holtz TH; Samandari T; Choopanya K;
    Lancet HIV; 2017 Feb; 4(2):e59-e66. PubMed ID: 27866873
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Maximizing participant retention in a phase 2B HIV prevention trial in Kampala, Uganda: The MTN-003 (VOICE) Study.
    Wynne J; Muwawu R; Mubiru MC; Kamira B; Kemigisha D; Nakyanzi T; Kabwigu S; Nakabiito C; Kiweewa Matovu F
    HIV Clin Trials; 2018 Oct; 19(5):165-171. PubMed ID: 30370830
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Plasma Tenofovir Levels to Support Adherence to TDF/FTC Preexposure Prophylaxis for HIV Prevention in MSM in Los Angeles, California.
    Landovitz RJ; Beymer M; Kofron R; Amico KR; Psaros C; Bushman L; Anderson PL; Flynn R; Lee DP; Bolan RK; Jordan WC; Tseng CH; Dierst-Davies R; Rooney J; Wohl AR
    J Acquir Immune Defic Syndr; 2017 Dec; 76(5):501-511. PubMed ID: 28902074
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Single-Tablet Emtricitabine-Rilpivirine-Tenofovir as HIV Postexposure Prophylaxis in Men Who Have Sex With Men.
    Foster R; McAllister J; Read TR; Pierce AB; Richardson R; McNulty A; Carr A
    Clin Infect Dis; 2015 Oct; 61(8):1336-41. PubMed ID: 26123937
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States.
    Grohskopf LA; Chillag KL; Gvetadze R; Liu AY; Thompson M; Mayer KH; Collins BM; Pathak SR; Oʼhara B; Ackers ML; Rose CE; Grant RM; Paxton LA; Buchbinder SP
    J Acquir Immune Defic Syndr; 2013 Sep; 64(1):79-86. PubMed ID: 23466649
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Daily or on-demand oral tenofovir disoproxil fumarate/emtricitabine for HIV pre-exposure prophylaxis: experience from a hospital-based clinic in France.
    Noret M; Balavoine S; Pintado C; Siguier M; Brun A; Bauer R; Loze B; Leplatois A; Aslan A; Moudachirou K; Delaugerre C; Rozenbaum W; Molina JM
    AIDS; 2018 Sep; 32(15):2161-2169. PubMed ID: 30212403
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of tolerability with the co-formulation elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate for post-HIV exposure prophylaxis.
    Valin N; Fonquernie L; Daguenel A; Campa P; Anthony T; Guiguet M; Girard PM; Meyohas MC
    BMC Infect Dis; 2016 Nov; 16(1):718. PubMed ID: 27894270
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Preexposure Prophylaxis for the Prevention of HIV Infection: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Chou R; Evans C; Hoverman A; Sun C; Dana T; Bougatsos C; Grusing S; Korthuis PT
    JAMA; 2019 Jun; 321(22):2214-2230. PubMed ID: 31184746
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of Sex on the Pharmacokinetics and Pharmacodynamics of 1% Tenofovir Gel.
    Herold BC; Chen BA; Salata RA; Marzinke MA; Kelly CW; Dezzutti CS; McGowan I; Galaska B; Levy L; Piper JM; Hillier S; Hendrix CW
    Clin Infect Dis; 2016 Feb; 62(3):375-382. PubMed ID: 26508513
    [TBL] [Abstract][Full Text] [Related]  

  • 58. First year of pre-exposure prophylaxis implementation in France with daily or on-demand tenofovir disoproxil fumarate/emtricitabine.
    Siguier M; Mera R; Pialoux G; Ohayon M; Cotte L; Valin N; Ghosn J; Cua E; Pintado C; Chas J; Barriere G; Durand F; Molina JM
    J Antimicrob Chemother; 2019 Sep; 74(9):2752-2758. PubMed ID: 31219561
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Client-Centered Adherence Counseling with Adherence Measurement Feedback to Support Use of the Dapivirine Ring in MTN-025 (The HOPE Study).
    Balán IC; Giguere R; Lentz C; Kutner BA; Kajura-Manyindo C; Byogero R; Asiimwe FB; Makala Y; Jambaya J; Khanyile N; Chetty D; Soto-Torres L; Mayo A; Mgodi NM; Palanee-Phillips T; Baeten JM
    AIDS Behav; 2021 Feb; 25(2):447-458. PubMed ID: 32833192
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Preference of Oral Tenofovir Disoproxil Fumarate/Emtricitabine Versus Rectal Tenofovir Reduced-Glycerin 1% Gel Regimens for HIV Prevention Among Cisgender Men and Transgender Women Who Engage in Receptive Anal Intercourse with Men.
    Carballo-Diéguez A; Giguere R; Dolezal C; Leu CS; Balán IC; Brown W; Rael C; Richardson BA; Piper JM; Bekker LG; Chariyalertsak S; Chitwarakorn A; Gonzales P; Holtz TH; Liu A; Mayer KH; Zorrilla CD; Lama JR; McGowan I; Cranston RD;
    AIDS Behav; 2017 Dec; 21(12):3336-3345. PubMed ID: 29119473
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.